On November 21, 2019, Amgen acquired from Celgene Corporation the worldwide rights to Otezla® (apremilast).
The GOtezla® app is a resource for your patients that provides personalized tips, tools to track their symptoms, 24/7 access to nurses, and treatment reminders that can help your patients get started with Otezla® (apremilast)—all at no cost to them.*
*Data rates from carrier may apply.
Otezla® (apremilast) is indicated for the treatment of adult patients with moderate to severe plaque psoriasis who are candidates for phototherapy or systemic therapy.
Otezla is indicated for the treatment of adult patients with active psoriatic arthritis.
Otezla is indicated for the treatment of adult patients with oral ulcers associated with Behçet’s Disease.
Warnings and Precautions
Use in Specific Populations